Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Orchestra BioMed Holdings ( (OBIO) ) has provided an update.
On August 1, 2025, Orchestra BioMed Holdings announced the pricing of its underwritten public offering, which included 9,413,637 shares of common stock and pre-funded warrants, raising approximately $40 million. The proceeds will support the company’s atrioventricular interval modulation therapy program, the BACKBEAT study, the Virtue SAB program, and other research and development initiatives. The offering closed on August 4, 2025, and was part of a broader strategy to advance its cardiovascular care technologies.
The most recent analyst rating on (OBIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
Spark’s Take on OBIO Stock
According to Spark, TipRanks’ AI Analyst, OBIO is a Neutral.
The overall score for Orchestra BioMed Holdings reflects significant financial challenges and bearish technical indicators. However, the recent strategic capital infusion adds a positive tilt, suggesting potential growth opportunities if clinical milestones are met.
To see Spark’s full report on OBIO stock, click here.
More about Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. The company is developing AVIM therapy for hypertension and Virtue SAB for atherosclerotic artery disease, with strategic collaborations with Medtronic and Terumo.
Average Trading Volume: 274,194
Technical Sentiment Signal: Sell
Current Market Cap: $94.29M
For an in-depth examination of OBIO stock, go to TipRanks’ Overview page.